A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
- Conditions
- Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365
- Registration Number
- EUCTR2005-003707-37-BE
- Lead Sponsor
- PDL BioPharma, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 150
Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
1) Males and females, 18 years of age or older.
2) Diagnosis of UC, as verified by endoscopy performed within 60 months prior to consent.
3) Severe active disease, as defined by MTWSI = 11 at consent, with a confirmatory MTWSI = 10 on or after the fifth consecutive day of IV steroids and within 1 day prior to randomization.
4) Mayo score = 10 and a Mayo mucosal subscore (finding of flexible proctosigmoidoscopy) of = 2. The Mayo score will be calculated on the day of sigmoidoscopy by a blinded gastroenterologist, after a minimum of 3 consecutive days (ie, on or after the fourth consecutive day) of IV steroids.
5) Agreement to use adequate contraception by male or female subjects of reproductive potential throughout the study and for 3 months after receiving the last dose of study drug.
6) Negative serum pregnancy test at screening in female subjects of childbearing potential.
7) Negative Clostridium difficile test within 10 days prior to the first dose of study drug.
8) Ability to understand the purpose and risks of the study and provide signed and dated informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria:
Subjects will be ineligible for this study if they meet any one of the following criteria:
1) UC requiring immediate surgical, endoscopic, or radiologic interventions, including massive hemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or perianal abscesses), or toxic megacolon requiring imminent intervention.
2) History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis.
3) Presence of ileostomy.
4) White blood cell (WBC) count less than 2.5 x 10^3/mcL; platelet count less than 150 x 10^3/mcL; or hemoglobin (Hgb) level less than 8 g/dL. Note the following exceptions for WBC counts only (minimum platelet counts and Hgb levels are the same):
a) If subject has been taking the same dose of AZA/6-MP/MTX for 30 or more consecutive days immediately prior to consent, a WBC count <2.0 x 10^3/mcL.
b) If subject has initiated treatment with, or increased his/her dose of, 6-MP, AZA, or MTX within 30 days prior to consent, a WBC count of = 5 x 10^3/mcL at the time of screening.
5) Active medically significant infections, particularly those of viral etiology, eg, known CMV colitis. This includes any incidence of medically significant opportunistic infections (see Definitions) within the past 12 months.
6) Subjects may not receive a live vaccine within 6 weeks prior to randomization, during the visilizumab dosing period, or for 60 days after receiving the last dose of study drug.
7) Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality (eg, creatinine =1.6 mg/dL; ALT or AST = 2X the upper limit of normal [ULN]; alkaline phosphatase =1.5X ULN); a history of myocardial infarction, coronary artery disease, congestive heart failure, or arrhythmias within 6 months prior to consent.
8) History or treatment of lymphoproliferative disorder (LPD) or malignancy within the past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).
9) Seropositive for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV) antibody.
10) Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2 weeks of randomization.
11) Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.
12) Treatment with any other investigational drug or therapy within 60 days prior to randomization, except those mentioned in the above two exclusion criteria.
13) Any condition that, in the investigator’s opinion, makes the subject unsuitable for study participation.
14) Pregnancy or nursing.
15) Nontherapeutic levels of chronic anti-seizure medications in subjects with a prior history of seizures, as tested within 4 days prior to randomization.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC).;Secondary Objective: 1) To compare the safety of visilizumab to placebo in IVSR-UC subjects.<br><br>2) To compare the immunogenicity of visilizumab to placebo in IVSR-UC subjects.<br><br>3) To compare the health-related quality of life (HRQoL) and pharmacoeconomic outcomes of visilizumab to placebo in IVSR-UC subjects.;Primary end point(s): The primary endpoint is the comparison of the proportion of subjects who respond to treatment on Day 45 (± 4 days) in the visilizumab and placebo groups. A subject is defined as a responder if he/she has a = 3-point reduction in the total Mayo score from baseline, with the rectal bleeding subscore reduced by at least 1 point, or an actual rectal bleeding subscore of 0 to 1.
- Secondary Outcome Measures
Name Time Method